Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
American Journal of Physiology. Renal Physiology|July 4, 2024
Inducible deletion of the prostaglandin EP3 receptor in kidney tubules of male and female mice has no major effect on water homeostasisCristina Esteva-Font, Frank Geurts, Toke P K Hansen, et al.
Journal of the American Heart Association|February 16, 2024
Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney DiseaseFrank Geurts, Layal Chaker, Anna C van der Burgh, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 21, 2023
Kidney phosphate wasting predicts poor outcome in polycystic kidney diseaseLaixi Xue, Frank Geurts, Esther Meijer, et al.
Clinical Journal of the American Society of Nephrology : CJASN|August 14, 2023
Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney DiseaseFrank Geurts, Laixi Xue, Bart J Kramers, et al.
The Journal of Clinical Endocrinology and Metabolism|May 22, 2024
The Effect of Thiazide Diuretics on Urinary Prostaglandin E2 Excretion and Serum Sodium in the General PopulationFrank Geurts, Crissy F Rudolphi, Anissa Pelouto, et al.
Journal of the American Society of Nephrology : JASN|May 24, 2022
Effects of Short-Term Potassium Chloride Supplementation in Patients with CKDMartin Gritter, Rosa D Wouda, Stanley M H Yeung, et al.
Pharmacological Reviews|June 16, 2022
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug TargetingHui Lin, Frank Geurts, Luise Hassler, et al.
Clinical Science (London, England : 1979)|November 18, 2020
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetesErik J M van Bommel, Frank Geurts, Marcel H A Muskiet, et al.
Kidney International|December 4, 2019
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trialErik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, et al.
Pageof 1